Non-exclusive rebate agreement for brolucizumab medicines for the period 01/09/2026–31/08/2028

Summary

The tender concerns the conclusion of a rebate agreement for medicines containing brolucizumab. This is an open procedure for the supply of medicines, and DAK-Gesundheit intends to conclude agreements with as many interested pharmaceutical companies as possible. Bidders should note that the exact qualification, compliance and contract performance requirements must be checked in the tender documents.